The phenotypic variety of spinocerebellar ataxias (SCAs) not caused by CAG repeat expansion (polyglutamine SCA) is greater than expected. A collaboration directed by scientists of the Paris Brain Institute described seven variants of this disorder in 756 individuals, observing that age at onset and progression by gene and variant can occur from childhood to late adulthood with very different forms of the disease. Read More
The WW domain binding protein 4 (WBP4) is part of the early spliceosomal complex, and it has been previously shown to enhance splicing both in vitro and in vivo, as well as to regulate alternative splicing. At the ESHG meeting, researchers from Hebrew University of Jerusalem presented data from a study that aimed to delineate WBP4 in the context of human pathologies. Read More
Panbela Therapeutics Inc. has entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center for the evaluation of polyamine metabolic inhibitor... Read More
Researchers from Imperial College of Science, Technology and Medicine have reported results of preclinical evaluation of THEO-260, a novel oncolytic virus for the treatment of stromal-rich tumors. The candidate is currently in development for late-stage relapsed refractory ovarian cancer. Read More
Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s disease and Alzheimer’s disease. Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer. Read More
La Crosse virus (LACV) is one of the most common causes of arboviral encephalitis in children, which causes CNS damage owing to infection in children, but not adults. LACV pathology indicates significant breakdown of the blood-brain barrier, which is strengthened during developmental transition from child to adult. Read More
Edgewise Therapeutics Inc. has divulged pyridazinone compounds acting as myosin-2 (MYH2) (ATPase activity) inhibitors reported to be useful for the treatment of Duchenne muscular dystrophy, amyotrophic lateral sclerosis, encephalitis, spinal cord injury, phenylketonuria, cerebral palsy, Alzheimer’s disease and Parkinson’s disease, among others. Read More
MD Biopharm Co. Ltd. has described protein-glutamine γ-glutamyltransferase 2 (TGM2) inhibitors reported to be useful for the treatment of cancer, celiac disease, neurological, inflammatory and cardiovascular disorders. Read More
Colorectal cancer (CRC) is one of the digestive tract cancers with the highest prevalence. Cancer immunotherapy for CRC brings substantial benefit to patients, but the development of resistance mechanisms and relapsing processes along with immune escape call for new treatment options. Read More
